Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.
A blood protein helps identify which immunotherapy combination works best for liver cancer patients, enabling personalized treatment selection.
Using real-world data from the RELPEC Study Group and 48 Japanese HCC clinics, this study identified baseline DCP as a biomarker that modifies the relative effectiveness of two approved first-line HCC immunotherapy combinations. DCP-guided treatment selection could improve HCC outcomes by matching patients to the most effective combination immunotherapy regimen.
What the study was
- Study design
- Multicenter real-world retrospective study (48 Japanese clinics)
- Category
- Other
- Maturity
- Validated
- Journal
- Liver Int
Why it surfaced
Large real-world multicenter biomarker-guided immunotherapy selection study in unresectable HCC; DCP as differential predictive biomarker for two approved regimens; high clinical relevance for immuno-oncology treatment selection intelligence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.